An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Cutaneous leishmaniasis
Intracellular parasite
Kala-azar
Kinetoplastids
Phagolysosome
Journal
Acta parasitologica
ISSN: 1896-1851
Titre abrégé: Acta Parasitol
Pays: Switzerland
ID NLM: 9301947
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
10
08
2021
accepted:
09
12
2021
pubmed:
13
1
2022
medline:
26
5
2022
entrez:
12
1
2022
Statut:
ppublish
Résumé
The trypanosomatid protozoan parasite Leishmania donovani is the etiological agent of visceral leishmaniasis (VL) or kala-azar. The patients that have undergone treatment may still harbor the parasite and in a small fraction of the patients the disease re-erupts in the form of post kala-azar dermal leishmaniasis (PKDL). PKDL is a pathological condition found to be intermediate between VL and complete cure of VL. The PKDL disease progression is determined by the host immune response to L. donovani. The majority of the proteomic studies on L. donovani till date have been undertaken on parasites either isolated from kala-azar patients or on established laboratory strains of L. donovani. However, no proteomic information is available on the cutaneous localized isolates of L. donovani from PKDL patients. The promastigote stage of L. donovani isolate from PKDL patient was cultured and harvested. The cell lysates were trypsin digested, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The LC-MS/MS raw data were analyzed on Proteome Discoverer. Further bioinformatics analysis was carried out. In the present, we have used high-resolution mass spectrometry to map the global proteome of a L. donovani isolate from PKDL patient. This in-depth study resulted in the identification of 5537 unique proteins from PKDL isolate of L. donovani which covered 64% of its proteome. This study also identified proteins previously shown to be upregulated in PKDL L. donovani. This is the most in-depth proteome of Leishmania donovani parasite till date.
Sections du résumé
BACKGROUND
BACKGROUND
The trypanosomatid protozoan parasite Leishmania donovani is the etiological agent of visceral leishmaniasis (VL) or kala-azar. The patients that have undergone treatment may still harbor the parasite and in a small fraction of the patients the disease re-erupts in the form of post kala-azar dermal leishmaniasis (PKDL). PKDL is a pathological condition found to be intermediate between VL and complete cure of VL. The PKDL disease progression is determined by the host immune response to L. donovani. The majority of the proteomic studies on L. donovani till date have been undertaken on parasites either isolated from kala-azar patients or on established laboratory strains of L. donovani. However, no proteomic information is available on the cutaneous localized isolates of L. donovani from PKDL patients.
METHODS
METHODS
The promastigote stage of L. donovani isolate from PKDL patient was cultured and harvested. The cell lysates were trypsin digested, followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. The LC-MS/MS raw data were analyzed on Proteome Discoverer. Further bioinformatics analysis was carried out.
RESULTS
RESULTS
In the present, we have used high-resolution mass spectrometry to map the global proteome of a L. donovani isolate from PKDL patient. This in-depth study resulted in the identification of 5537 unique proteins from PKDL isolate of L. donovani which covered 64% of its proteome.
OUTCOME
RESULTS
This study also identified proteins previously shown to be upregulated in PKDL L. donovani. This is the most in-depth proteome of Leishmania donovani parasite till date.
Identifiants
pubmed: 35020128
doi: 10.1007/s11686-021-00511-3
pii: 10.1007/s11686-021-00511-3
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
687-696Subventions
Organisme : Department of Science and Technology, Ministry of Science and Technology
ID : DST-WOS-A
Informations de copyright
© 2022. The Author(s) under exclusive licence to Witold Stefański Institute of Parasitology, Polish Academy of Sciences.
Références
McCall LI, Zhang WW, Matlashewski G (2013) Determinants for the development of visceral leishmaniasis disease. PLoS Pathog 9:e1003053. https://doi.org/10.1371/journal.ppat.1003053
doi: 10.1371/journal.ppat.1003053
pubmed: 23300451
pmcid: 3536654
Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561–1577. https://doi.org/10.1016/S0140-6736(05)67629-5
doi: 10.1016/S0140-6736(05)67629-5
pubmed: 16257344
Killick-Kendrick R (1990) Phlebotomine vectors of the leishmaniases: a review. Med Vet Entomol 4:1–24. https://doi.org/10.1111/j.1365-2915.1990.tb00255.x
doi: 10.1111/j.1365-2915.1990.tb00255.x
pubmed: 2132963
Trindade MA, Silva LL, Braz LM, Amato VS, Naafs B, Sotto MN (2015) Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review. BMC Infect Dis 23:1–8. https://doi.org/10.1186/s12879-015-1260-x
doi: 10.1186/s12879-015-1260-x
WHO (2012) The Post Kala-azar Dermal Leishmaniasis (PKDL). In: Alvar EJ (ed) Atlas a manual for health workers. WHO, p 215
Zijlstra EE, Kumar A, Sharma A, Rijal S, Mondal D, Routray S (2020) Report of the Fifth Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Colombo, Sri Lanka, 14–16 May 2018. Parasit Vectors 13:159. https://doi.org/10.1186/s13071-020-04011-7
doi: 10.1186/s13071-020-04011-7
pubmed: 32228668
pmcid: 7106569
Hartley MA, Drexler S, Ronet C, Beverley SM, Fasel N (2014) The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis. Trends Parasitol 30:412–422. https://doi.org/10.1016/j.pt.2014.05.006
doi: 10.1016/j.pt.2014.05.006
pubmed: 24954794
pmcid: 4287268
Mondal D, Kumar A, Sharma A, Ahmed MM, Hasnain MG, Alim A et al (2019) Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: a cohort study from Bangladesh. PLoS Negl Trop Dis 15:1–16. https://doi.org/10.1371/journal.pntd.0007653
doi: 10.1371/journal.pntd.0007653
Ganguly S, Saha P, Chatterjee M, Roy S, Ghosh TK, Guha SK et al (2015) PKDL–A silent parasite pool for transmission of leishmaniasis in Kala-azar Endemic Areas of Malda District West Bengal, India. PLoS Negl Trop Dis. https://doi.org/10.1371/journal.pntd.0004138
doi: 10.1371/journal.pntd.0004138
pubmed: 26485704
pmcid: 4613818
Mondal D, Khan MG (2011) Recent advances in post-kala-azar dermal leishmaniasis. Curr Opin Infect Dis 24:418–422. https://doi.org/10.1097/QCO.0b013e32834a8ba1
doi: 10.1097/QCO.0b013e32834a8ba1
pubmed: 21885919
Uranw S, Ostyn B, Rijal A, Devkota S, Khanal B, Menten J et al (2011) Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000–2010). PLoS Negl Trop Dis 5:1–7. https://doi.org/10.1371/journal.pntd.0001433
doi: 10.1371/journal.pntd.0001433
Pandey K, Verma N, Lal CS, Bimal S, Topno RK, Singh D et al (2009) Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis. Am J Trop Med Hyg 80:336–338. https://doi.org/10.4103/0022-3859.118046
doi: 10.4103/0022-3859.118046
pubmed: 19270277
Gedda MR, Singh B, Kumar D, Singh AK, Madhukar P, Upadhyay S et al (2020) Post kala-azar dermal leishmaniasis: a threat to elimination program. PLoS Negl Trop Dis 14:1–25. https://doi.org/10.1371/journal.pntd.0008221
doi: 10.1371/journal.pntd.0008221
Inbar E, Lawyer P, Sacks D, Podini D (2016) The potential use of forensic DNA methods applied to sand fly blood meal analysis to identify the infection reservoirs of anthroponotic visceral leishmaniasis. PLoS Negl Trop Dis 10:e0004706. https://doi.org/10.1371/journal.pntd.0004706
doi: 10.1371/journal.pntd.0004706
pubmed: 27192489
pmcid: 4871566
Al-Salem W, Herricks JR, Hotez PJ (2016) A review of visceral leishmaniasis during the conflict in South Sudan and the consequences for East African countries. Parasit Vectors 9:460. https://doi.org/10.1186/s13071-016-1743-7
doi: 10.1186/s13071-016-1743-7
pubmed: 27549162
pmcid: 4994383
Kip AE, Balasegaram M, Beijnen JH, Schellens JH, de Vries PJ, Dorlo TP (2015) Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother 59:1–14. https://doi.org/10.1128/AAC.04298-14
doi: 10.1128/AAC.04298-14
pubmed: 25367913
Zijlstra EE (2019) Biomarkers in Post-kala-azar Dermal Leishmaniasis. Front Cell Infect Microbiol 9:228. https://doi.org/10.3389/fcimb.2019.00228
doi: 10.3389/fcimb.2019.00228
pubmed: 31417876
pmcid: 6685405
Bar Routaray C, Bhor R, Bai S, Kadam NS, Jagtap S, Doshi PJ et al (2020) SWATH-MS based quantitative proteomics analysis to evaluate the antileishmanial effect of Commiphora wightii-Guggul and Amphotericin B on a clinical isolate of Leishmania donovani. J Proteom. https://doi.org/10.1016/j.jprot.2020.103800
doi: 10.1016/j.jprot.2020.103800
Goyal V, Das VNR, Singh SN, Singh RS, Pandey K, Verma N et al (2020) Long-term incidence of relapse and post-kala-azar dermal leishmaniasis after three different visceral leishmaniasis treatment regimens in Bihar, India. PLoS Negl Trop Dis 14:e0008429. https://doi.org/10.1371/journal.pntd.0008429
doi: 10.1371/journal.pntd.0008429
pubmed: 32687498
pmcid: 7392342
Salotra P, Duncan RC, Singh RS, Raju BV, Sreenivas G, Nakhasi HL (2005) Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect 8:637–644. https://doi.org/10.1016/j.micinf.2005.08.018
doi: 10.1016/j.micinf.2005.08.018
Gupta AK, Srivastava S, Singh A, Singh S (2015) De novo whole-genome sequence and annotation of a leishmania strain isolated from a case of post-Kala-Azar Dermal leishmaniasis. Genome Announc 3:2. https://doi.org/10.1128/genomeA.00809-15
doi: 10.1128/genomeA.00809-15
Camacho E, Gonzalez-de la Fuente S, Rastrojo A, Peiro-Pastor R, Solana JC, Tabera L et al (2019) Complete assembly of the Leishmania donovani (HU3 strain) genome and transcriptome annotation. Sci Rep 9:6127. https://doi.org/10.1038/s41598-019-42511-4
doi: 10.1038/s41598-019-42511-4
pubmed: 30992521
pmcid: 6467909
Lypaczewski P, Hoshizaki J, Zhang WW, McCall LI, Torcivia-Rodriguez J, Simonyan V et al (2018) A complete Leishmania donovani reference genome identifies novel genetic variations associated with virulence. Sci Rep 8:16549. https://doi.org/10.1038/s41598-018-34812-x
doi: 10.1038/s41598-018-34812-x
pubmed: 30409989
pmcid: 6224596
Pawar H, Sahasrabuddhe NA, Renuse S, Keerthikumar S, Sharma J, Kumar GS et al (2012) A proteogenomic approach to map the proteome of an unsequenced pathogen—Leishmania donovani. Proteomics 12:832–844. https://doi.org/10.1002/pmic.201100505
doi: 10.1002/pmic.201100505
pubmed: 22539434
Nirujogi RS, Pawar H, Renuse S, Kumar P, Chavan S, Sathe G et al (2013) Moving from unsequenced to sequenced genome: Reanalysis of the proteome of Leishmania donovani. J Proteom. https://doi.org/10.1016/j.jprot.2013.04.021
doi: 10.1016/j.jprot.2013.04.021
Pawar H, Sathe G, Patole MS (2020) Genome-wide proteomics and phosphoproteomics analysis of Leishmania spp. during differentiation. Methods Mol Biol 2116:161–176. https://doi.org/10.1007/978-1-0716-0294-2_12
doi: 10.1007/978-1-0716-0294-2_12
pubmed: 32221921
Wei FR, Gao CH, Wang JY, Yang YT, Shi F, Zheng B (2021) Label-free quantitative proteomic analysis of three strains of viscerotropic leishmania isolated from patients with different epidemiological types of visceral leishmaniasis in China. Acta Parasitol. https://doi.org/10.1007/s11686-021-00387-3
doi: 10.1007/s11686-021-00387-3
pubmed: 34019278
Siriwardana Y, Zhou G, Deepachandi B, Akarawita J, Wickremarathne C, Warnasuriya W et al (2019) Trends in recently emerged Leishmania donovani induced cutaneous leishmaniasis, Sri Lanka, for the First 13 Years. Biomed Res Int 2019:4093603. https://doi.org/10.1155/2019/4093603
doi: 10.1155/2019/4093603
pubmed: 31111052
pmcid: 6487155
Zhang WW, Ramasamy G, McCall LI, Haydock A, Ranasinghe S, Abeygunasekara P et al (2014) Genetic analysis of Leishmania donovani tropism using a naturally attenuated cutaneous strain. PLoS Pathog 10:e1004244. https://doi.org/10.1371/journal.ppat.1004244
doi: 10.1371/journal.ppat.1004244
pubmed: 24992200
pmcid: 4081786
Dumetz F, Imamura H, Sanders M, Seblova V, Myskova J, Pescher P et al (2017) Modulation of aneuploidy in Leishmania donovani during adaptation to different in vitro and in vivo environments and its impact on gene expression. MBio. https://doi.org/10.1128/mBio.00599-17
doi: 10.1128/mBio.00599-17
pubmed: 28536289
pmcid: 5442457
Kulak NA, Pichler G, Paron I, Nagaraj N, Mann M (2014) Minimal, encapsulated proteomic-sample processing applied to copy-number estimation in eukaryotic cells. Nat Methods 11:319–324. https://doi.org/10.1038/nmeth.2834
doi: 10.1038/nmeth.2834
pubmed: 24487582
Pawar H, Kulkarni A, Dixit T, Chaphekar D, Patole MS (2014) A bioinformatics approach to reanalyze the genome annotation of kinetoplastid protozoan parasite Leishmania donovani. Genomics 104:554–561. https://doi.org/10.1016/j.ygeno.2014.09.008
doi: 10.1016/j.ygeno.2014.09.008
pubmed: 25265881
Salotra P, Duncan RC, Singh RS, Raju BV, Sreenivas G, Nakhasi HL (2006) Upregulation of surface proteins in Leishmania donovani isolated from patients of post kala-azar dermal leishmaniasis. Microbes Infect 8:637–644. https://doi.org/10.1016/j.micinf.2005.08.018
doi: 10.1016/j.micinf.2005.08.018
pubmed: 16469521
Stober CB, Lange UG, Roberts MT, Gilmartin B, Francis R, Almeida R et al (2006) From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 24:2602–2616. https://doi.org/10.1016/j.vaccine.2005.12.012
doi: 10.1016/j.vaccine.2005.12.012
pubmed: 16406227
Zhang J, He J, Li J, Zhou Q, Chen H, Zheng Z et al (2020) The immunogenicity and protective immunity of multi-epitopes DNA prime-protein boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis. PLoS ONE 15:e0230381. https://doi.org/10.1371/journal.pone.0230381
doi: 10.1371/journal.pone.0230381
pubmed: 32176727
pmcid: 7075555
Rafati S, Hassani N, Taslimi Y, Movassagh H, Rochette A, Papadopoulou B (2006) Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin Vaccine Immunol 13:1104–1110. https://doi.org/10.1128/CVI.00188-06
doi: 10.1128/CVI.00188-06
pubmed: 17028214
pmcid: 1595312
Sharma P, Gurumurthy S, Duncan R, Nakhasi HL, Salotra P (2010) Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis. Parasitol Int 59:262–264. https://doi.org/10.1016/j.parint.2009.11.003
doi: 10.1016/j.parint.2009.11.003
pubmed: 19963076
McNicoll F, Drummelsmith J, Muller M, Madore E, Boilard N, Ouellette M et al (2006) A combined proteomic and transcriptomic approach to the study of stage differentiation in Leishmania infantum. Proteomics 6:3567–3581. https://doi.org/10.1002/pmic.200500853
doi: 10.1002/pmic.200500853
pubmed: 16705753
Subba Raju BV, Singh R, Sreenivas G, Singh S, Salotra P (2008) Genetic fingerprinting and identification of differentially expressed genes in isolates of Leishmania donovani from Indian patients of post-kala-azar dermal leishmaniasis. Parasitology 135:23–32. https://doi.org/10.1017/S0031182007003484
doi: 10.1017/S0031182007003484
pubmed: 17761024
Ati J, Colas C, Lafite P, Sweeney RP, Zheng RB, Lowary TL et al (2018) The LPG1x family from Leishmania major is constituted of rare eukaryotic galactofuranosyltransferases with unprecedented catalytic properties. Sci Rep 8:17566. https://doi.org/10.1038/s41598-018-35847-w
doi: 10.1038/s41598-018-35847-w
pubmed: 30514885
pmcid: 6279836
Azevedo LG, de Queiroz ATL, Barral A, Santos LA, Ramos PIP (2020) Proteins involved in the biosynthesis of lipophosphoglycan in Leishmania: a comparative genomic and evolutionary analysis. Parasit Vectors 13:44. https://doi.org/10.1186/s13071-020-3914-9
doi: 10.1186/s13071-020-3914-9
pubmed: 32000835
pmcid: 6993435
Lazaro-Souza M, Matte C, Lima JB, Arango Duque G, Quintela-Carvalho G, de Carvalho Vivarini A et al (2018) Leishmania infantum lipophosphoglycan-deficient mutants: a tool to study host cell-parasite interplay. Front Microbiol 9:626. https://doi.org/10.3389/fmicb.2018.00626
doi: 10.3389/fmicb.2018.00626
pubmed: 29675001
pmcid: 5896263
Kariyawasam U, Selvapandiyan A, Rai K, Wani T, Ahuja K, Beg M et al (2017) Genetic diversity of Leishmania donovani that causes cutaneous leishmaniasis in Sri Lanka: a cross sectional study with regional comparisons. BMC Infect Dis 17:791. https://doi.org/10.1186/s12879-017-2883-x
doi: 10.1186/s12879-017-2883-x
pubmed: 29273010
pmcid: 5741890
Samarasinghe SR, Samaranayake N, Kariyawasam UL, Siriwardana YD, Imamura H, Karunaweera ND (2018) Genomic insights into virulence mechanisms of Leishmania donovani: evidence from an atypical strain. BMC Genom 19:843. https://doi.org/10.1186/s12864-018-5271-z
doi: 10.1186/s12864-018-5271-z
Kraus AJ, Brink BG, Siegel TN (2019) Efficient and specific oligo-based depletion of rRNA. Sci Rep 9:12281. https://doi.org/10.1038/s41598-019-48692-2
doi: 10.1038/s41598-019-48692-2
pubmed: 31439880
pmcid: 6706579
Doyon Y, Selleck W, Lane W, Tan S, Côté J (2004) Structural and functional conservation of the NuA4 histone acetyltransferase complex from yeast to humans. Mol Cell Biol 24:1884–1896. https://doi.org/10.1128/MCB.24.5.1884-1896.2004
doi: 10.1128/MCB.24.5.1884-1896.2004
pubmed: 14966270
pmcid: 350560
Kumar D, Rajanala K, Minocha N, Saha S (2012) Histone H4 lysine 14 acetylation in Leishmania donovani is mediated by the MYST-family protein HAT4. Microbiology (Reading) 158:328–337. https://doi.org/10.1099/mic.0.050211-0
doi: 10.1099/mic.0.050211-0
Lye LF, Cunningham ML, Beverley SM (2002) Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major. J Biol Chem 277:38245–38253. https://doi.org/10.1074/jbc.M206543200
doi: 10.1074/jbc.M206543200
pubmed: 12151409
Marchini JF, Cruz AK, Beverley SM, Tosi LR (2003) The H region HTBF gene mediates terbinafine resistance in Leishmania major. Mol Biochem Parasitol 131:77–81. https://doi.org/10.1016/S0166-6851(03)00174-9
doi: 10.1016/S0166-6851(03)00174-9
pubmed: 12967714
Franssen SU, Durrant C, Stark O, Moser B, Downing T, Imamura H et al (2020) Global genome diversity of the Leishmania donovani complex. Elife. https://doi.org/10.7554/eLife.51243.sa2
doi: 10.7554/eLife.51243.sa2
pubmed: 32209228
pmcid: 7105377
Jesus-Santos FH, Lobo-Silva J, Ramos PIP, Descoteaux A, Lima JB, Borges VM, Farias LP (2020) LPG2 gene duplication in Leishmania infantum: a case for CRISPR-Cas9 gene editing. Front Cell Infect Microbiol 10:408. https://doi.org/10.3389/fcimb.2020.00408